Adjuvant Therapy for Stage IB Germ Cell Tumors: One versus Two Cycles of BEP.

about

Adjuvant Therapy for Stage IB Germ Cell Tumors: One versus Two Cycles of BEP.

Item

http://www.wikidata.org/entity/Q55317807

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Adjuvant Therapy for Stage IB Germ Cell Tumors: One versus Two Cycles of BEP.

@en

Adjuvant Therapy for Stage IB Germ Cell Tumors: One versus Two Cycles of BEP.

@nl

type

Item

label

Adjuvant Therapy for Stage IB Germ Cell Tumors: One versus Two Cycles of BEP.

@en

Adjuvant Therapy for Stage IB Germ Cell Tumors: One versus Two Cycles of BEP.

@nl

prefLabel

Adjuvant Therapy for Stage IB Germ Cell Tumors: One versus Two Cycles of BEP.

@en

Adjuvant Therapy for Stage IB Germ Cell Tumors: One versus Two Cycles of BEP.

@nl

P1476

Adjuvant Therapy for Stage IB Germ Cell Tumors: One versus Two Cycles of BEP.

@en

P2093

Alison M Reid

http://www.w3.org/2001/XMLSchema#string

P2860

Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer

Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors.

Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review.

Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion.

Development and Validation of a Gene-Based Model for Outcome Prediction in Germ Cell Tumors Using a Combined Genomic and Expression Profiling Approach.

A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion

Defining a New Prognostic Index for Stage I Nonseminomatous Germ Cell Tumors Using CXCL12 Expression and Proportion of Embryonal Carcinoma.

Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17).

Testicular germ cell tumours.

The present and future of serum diagnostic tests for testicular germ cell tumours.

P304

8781698

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2018/8781698

http://www.w3.org/2001/XMLSchema#string

P478

2018

http://www.w3.org/2001/XMLSchema#string

P50

Robert Huddart

P577

2018-04-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29808086

http://www.w3.org/2001/XMLSchema#string

P932

5902120

http://www.w3.org/2001/XMLSchema#string